HS-683 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Brain cancer cell lines |
| Organism |
Human |
| Donor History |
Oligodendroglioma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: DMEM ,w: 4.5 g/L Glucose ,w: 4 mM L-Glutamine ,w: 3.7 g/L NaHCO3 ,w: 1.0 mM Sodium pyruvate (Cytion article number 820300a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: When seeded at 1 x 10⁴ cells/cm² the cells will reach 80% confluence within 3 to 4 d. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
HS-683 is a human glioma cell line derived from the brain tissue of an adult patient diagnosed with glioblastoma multiforme. Glioblastoma multiforme is a highly aggressive type of brain cancer, known for its rapid growth and poor prognosis. The HS-683 cell line is valuable in cancer research due to its ability to provide insights into the molecular mechanisms driving glioma proliferation, invasion, and resistance to therapies.
HS-683 cells exhibit many characteristics typical of glioma cells, including high proliferative capacity and the expression of markers such as GFAP (glial fibrillary acidic protein), which is indicative of their glial origin. These cells are commonly used in studies investigating the efficacy of chemotherapeutic agents, radiation treatments, and novel targeted therapies. Researchers utilize HS-683 to explore genetic and epigenetic alterations, signal transduction pathways, and the tumor microenvironment’s role in glioma progression. The HS-683 cell line, therefore, serves as a crucial model for developing and testing new therapeutic strategies aimed at improving outcomes for patients with glioblastoma.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

